Your browser doesn't support javascript.
loading
A2BCD: a concise guide for asthma management.
Lommatzsch, Marek; Brusselle, Guy G; Levy, Mark L; Canonica, G Walter; Pavord, Ian D; Schatz, Michael; Virchow, Johann Christian.
Afiliação
  • Lommatzsch M; Department of Pneumology, University of Rostock, Rostock, Germany. Electronic address: marek.lommatzsch@med.uni-rostock.de.
  • Brusselle GG; Department of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium.
  • Levy ML; Locum General Practitioner, London, UK.
  • Canonica GW; Department of Biomedical Sciences, Humanitas University, Milan, Italy; Personalized Medicine Asthma and Allergy, IRCCS Humanitas Research Hospital, Milan, Italy.
  • Pavord ID; National Institute for Health Research Oxford Biomedical Research Centre, and Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Schatz M; Allergy Department, Kaiser Permanente San Diego Medical Center, San Diego, CA, USA.
  • Virchow JC; Department of Pneumology, University of Rostock, Rostock, Germany.
Lancet Respir Med ; 11(6): 573-576, 2023 06.
Article em En | MEDLINE | ID: mdl-36716752
The management of asthma has changed fundamentally during the past two decades. Precise assessment and phenotyping are now required to establish individually targeted treatment with disease-modifying anti-asthmatic drugs (DMAADs). Patients with asthma are often managed by primary care doctors or non-respiratory specialists in secondary care. However, the implementation of complex asthma guidelines in non-specialised care remains a challenge. There is a need for easy-to-understand, concise guides for general practice. In this Viewpoint, we propose a one-page practical guide for asthma management, titled A2BCD, with four components: dual assessment (A2) of asthma (ie, diagnosis and phenotype, plus asthma control and future risks); basic measures (B; eg, education, self-management skills, regular physical activity, and avoidance of asthma triggers); identification and treatment of comorbidities (C) of asthma (eg, chronic rhinosinusitis, obesity, or sleep apnoea); and phenotype-specific, individually targeted treatment with DMAADs (D), including individual inhalation schemes based on inhaled corticosteroids, leukotriene modifiers, biologics, and allergen immunotherapy.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Asma / Antiasmáticos Tipo de estudo: Diagnostic_studies / Guideline / Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Asma / Antiasmáticos Tipo de estudo: Diagnostic_studies / Guideline / Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article